Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental combo therapy for blood cancers shows early safety data

NCT ID NCT03940352

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 31 times

Summary

This early-stage study tested two new drug combinations in 52 adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), types of blood and bone marrow cancer. The goal was to find safe doses and understand side effects. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Duke University Medical Center .

    Durham, North Carolina, 27710, United States

  • Novartis Investigative Site

    Melbourne, Victoria, 3004, Australia

  • Novartis Investigative Site

    Helsinki, FIN 00290, Finland

  • Novartis Investigative Site

    Heidelberg, 69120, Germany

  • Novartis Investigative Site

    Würzburg, 97080, Germany

  • Novartis Investigative Site

    Milan, MI, 20132, Italy

  • Novartis Investigative Site

    Roma, RM, 00161, Italy

  • Novartis Investigative Site

    Singapore, 119228, Singapore

  • Novartis Investigative Site

    Madrid, 28041, Spain

Conditions

Explore the condition pages connected to this study.

ACUTE MYELOID LEUKEMIA (AML) HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)